Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Companion animal trials to help human patients
Professor Wouda
The study focuses on dogs because of the similarities between their cancers and human cancers.

Researchers test innovative treatment options 

Clinical trials to treat cancers in cats, dogs, and other companion animals are underway at Kansas State University.

Raelene Wouda, assistant professor of clinical sciences, is offering groundbreaking new treatments to pet owners at a reduced cost.

In addition to improved diagnostic testing and monitoring approaches, the trials include innovative treatment options including combination chemotherapy, t-cell transfer and nanoparticle drug formulations.


As well as improving outcomes for veterinary patients, Wouda hopes the research will provide important information for how the disease can be better diagnosed, monitored and treated in humans.


“For many pet owners, cancer is a terminal diagnosis for they beloved family member,” Wouda said. “These studies provide an opportunity to trial a cutting-edge therapy for their pets at a reasonable price.”

“Moreover, owners participating in these clinical trials take comfort and are pleased to know that they are helping to achieve better treatments and outcomes for pets that may be diagnosed with cancer in the future.”

Professor Wouda’s research, published in the journal Veterinary Comparative Oncology, has been described as a ‘crucial step’ towards a long-term cure for many cancers.

The study focuses on dogs because of the similarities between their cancers and human cancers, like melanoma, lung cancer and osteosarcoma.


Dogs also live with us and are exposed to the same environmental factors, explained Wouda. Furthermore, because dogs age faster than humans, their disease progresses faster, which is a practical advantage for evaluating the efficacy and clinical benefits of new treatments.

"We get clinical answers more quickly in dogs," Wouda said. "The benefit of a particular therapy becomes evident in dogs more rapidly compared to people, and because of this we can preserve research and development finances, but more importantly, we save valuable time and resources."

Professor Wouda will work with graduate students, oncology technicians and referral veterinary surgeons to conduct the clinical trials.

She will also collaborate with human medical researchers to discuss how the research can be best applied to the field of human oncology.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.